See more : Westpac Banking Corporation (WBC.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Zentalis Pharmaceuticals, Inc. (ZNTL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zentalis Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zhongchao Inc. (ZCMD) Income Statement Analysis – Financial Results
- Australian Clinical Labs Limited (ACL.AX) Income Statement Analysis – Financial Results
- Pfizer Inc. (PFE.NE) Income Statement Analysis – Financial Results
- New World Brands, Inc. (NWBD) Income Statement Analysis – Financial Results
- Qliro AB (publ) (QLIRO.ST) Income Statement Analysis – Financial Results
Zentalis Pharmaceuticals, Inc. (ZNTL)
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K |
| Cost of Revenue | 1.39M | 1.43M | 544.00K | 160.00K | 111.00K | 0.00 |
| Gross Profit | -1.39M | -1.43M | -544.00K | -160.00K | -111.00K | 14.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 189.59M | 172.73M | 175.60M | 84.90M | 38.39M | 18.92M |
| General & Administrative | 59.40M | 54.55M | 40.94M | 33.89M | 8.46M | 4.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.40M | 54.55M | 40.94M | 33.89M | 8.46M | 4.88M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -16.00K | 0.00 |
| Operating Expenses | 252.55M | 227.29M | 216.54M | 118.79M | 46.85M | 23.80M |
| Cost & Expenses | 253.94M | 227.29M | 216.54M | 118.79M | 46.85M | 23.80M |
| Interest Income | 0.00 | 2.26K | 1.31K | 1.24K | 498.00K | 355.00K |
| Interest Expense | 0.00 | 2.58M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.39M | 1.43M | 544.00K | 160.00K | 111.00K | 51.49K |
| EBITDA | -275.50M | -219.87M | -164.02M | -117.94M | -46.73M | -23.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -169,514.29% |
| Operating Income | -248.99M | -227.29M | -216.54M | -118.79M | -46.85M | -23.78M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -169,878.57% |
| Total Other Income/Expenses | -27.90M | 5.99M | 51.98M | 683.00K | 482.00K | 355.00K |
| Income Before Tax | -276.89M | -221.30M | -164.56M | -118.10M | -46.36M | -23.43M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -167,342.86% |
| Income Tax Expense | -601.00K | -469.00K | -297.00K | 444.00K | 15.00K | 4.00K |
| Net Income | -292.19M | -220.83M | -164.26M | -118.55M | -46.38M | -21.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -150,478.57% |
| EPS | -4.47 | -4.18 | -3.85 | -2.89 | -1.29 | -1.17 |
| EPS Diluted | -4.47 | -4.18 | -3.85 | -2.89 | -1.29 | -1.17 |
| Weighted Avg Shares Out | 65.41M | 52.86M | 42.69M | 41.04M | 35.88M | 18.06M |
| Weighted Avg Shares Out (Dil) | 65.41M | 52.86M | 42.69M | 41.04M | 35.88M | 18.06M |
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Zentalis Pharmaceuticals, Inc. (ZNTL)
ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm!
Did Zentalis Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ZNTL
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
ATTENTION Zentalis Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zentalis (ZNTL)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Source: https://incomestatements.info
Category: Stock Reports
What are Zentalis Pharmaceuticals’ Q2 2024 financial highlights?
Cash, Cash Equivalents and Marketable Securities Position: As of June 30, 2024, Zentalis had cash, cash equivalents and marketable securities of $426.4 million, which includes $27.8 million representing the June 30, 2024 fair value of Immunome common stock received by the Company as part of its upfront payment for the …